Ebiratide (HOE-427) TFA is an ACTH 4-9 derivative, which acts directly on the central nervous system and exhibits memory-enhancing efficacy. Ebiratide TFA enhances acetycholine (ACh) metabolism in rat brain [1] [2].
In Vivo, Ebiratide (0.1-30 μg/kg, s.c., single dose) TFA exhibits neuroprotective efficacy in electoconvulsive shock and Scopolamine -induced memory impairment in mice model, exhibits anti-amnestic efficacy[1].
References:
[1]. Hock FJ, et al., Learning and memory processes of an ACTH4-9 analog (ebiratide; Hoe 427) in mice and rats. Peptides. 1988 May-Jun;9(3):575-81.
[2]. G Wiemer, et al. Neurochemical effects of the synthetic ACTH4-9-analog Hoe 427 (Ebiratide) in rat brain. Peptides. 1988 Sep-Oct;9(5):1081-7.
In Vivo, Ebiratide (0.1-30 μg/kg, s.c., single dose) TFA exhibits neuroprotective efficacy in electoconvulsive shock and Scopolamine -induced memory impairment in mice model, exhibits anti-amnestic efficacy[1].
References:
[1]. Hock FJ, et al., Learning and memory processes of an ACTH4-9 analog (ebiratide; Hoe 427) in mice and rats. Peptides. 1988 May-Jun;9(3):575-81.
[2]. G Wiemer, et al. Neurochemical effects of the synthetic ACTH4-9-analog Hoe 427 (Ebiratide) in rat brain. Peptides. 1988 Sep-Oct;9(5):1081-7.